NASDAQ:ERAS Erasca (ERAS) Stock Price, News & Analysis $2.86 -0.13 (-4.35%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.81▼$3.0650-Day Range$2.17▼$3.2852-Week Range$1.51▼$3.45Volume2.53 million shsAverage Volume1.54 million shsMarket Capitalization$495.81 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Erasca alerts: Email Address Erasca MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside109.8% Upside$6.00 Price TargetShort InterestBearish14.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.91) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 starsMedical Sector643rd out of 910 stocksPharmaceutical Preparations Industry294th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingErasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageErasca has only been the subject of 2 research reports in the past 90 days.Read more about Erasca's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.11% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently increased by 5.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERAS. Previous Next 1.8 News and Social Media Coverage News SentimentErasca has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Erasca this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have not sold or bought any company stock.Percentage Held by Insiders21.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Erasca's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Erasca are expected to grow in the coming year, from ($0.91) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Erasca's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Erasca Stock (NASDAQ:ERAS)Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Read More ERAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERAS Stock News HeadlinesSeptember 3, 2024 | americanbankingnews.comErasca, Inc. (NASDAQ:ERAS) Sees Large Increase in Short InterestAugust 29, 2024 | finance.yahoo.comErasca to Present at Upcoming Investor Conferences in SeptemberSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 15, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Buy Rating on Erasca (ERAS)August 15, 2024 | uk.investing.comErasca stock target raised on SEACRAFT-2 study optimismAugust 15, 2024 | finance.yahoo.comWe're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash WiselyAugust 13, 2024 | markets.businessinsider.comErasca Inc. Poised for Growth: Buy Rating Maintained Amidst Promising Trial Updates and Solid FinancialsAugust 13, 2024 | markets.businessinsider.comErasca’s Innovative Melanoma Treatments Prompt Buy RatingSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 12, 2024 | globenewswire.comErasca Reports Second Quarter 2024 Business Updates and Financial ResultsMay 29, 2024 | globenewswire.comErasca to Present at Upcoming Investor Conferences in JuneMay 23, 2024 | finance.yahoo.comIndependent Director of Erasca Picks Up 14% More StockMay 21, 2024 | finance.yahoo.comErasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesMay 21, 2024 | globenewswire.comErasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesMay 20, 2024 | markets.businessinsider.comErasca Inc. Earns Buy Rating: Strategic Acquisitions and Promising Pipeline PositioningMay 20, 2024 | markets.businessinsider.comOptimistic Outlook for Erasca: Strategic Growth and Financial PrudenceMay 17, 2024 | msn.comErasca stock climbs 10% amid pipeline restructuring, equity offeringMay 16, 2024 | globenewswire.comErasca Announces Strategic In-Licensing of RAS-Targeting FranchiseSee More Headlines Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside+109.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.38% Return on Assets-37.01% Debt Debt-to-Equity RatioN/A Current Ratio16.79 Quick Ratio16.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book1.79Miscellaneous Outstanding Shares173,359,000Free Float136,087,000Market Cap$495.81 million OptionableOptionable Beta1.16 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jonathan E. Lim M.D. (Age 52)Co-Founder, Chairman & CEO Comp: $940.32kDr. David M. Chacko M.D. (Age 40)CFO & Chief Business Officer Comp: $616.76kDr. Michael D. Varney Ph.D. (Age 66)Chairman of Research & Development, Scientific Advisory Board Member and Director Comp: $83.26kDr. Nik Chetwyn Ph.D.Chief Operating OfficerMr. Ebun S. Garner J.D. (Age 52)Esq., General Counsel & Corporate Secretary Comp: $510.98kDr. Lisa Tesvich-Bonora Ph.D.Chief People OfficerMr. Brian L. Baker CPA (Age 57)M.S., Senior Vice President of Finance Ms. Chandra D. Lovejoy M.S. (Age 53)Chief Regulatory Affairs Officer Dr. Robert Shoemaker Ph.D. (Age 43)Senior Vice President of Research Dr. Shannon R. Morris M.D. (Age 54)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsVerve TherapeuticsNASDAQ:VERVNuvation BioNYSE:NUVBLyell ImmunopharmaNASDAQ:LYELBlack Diamond TherapeuticsNASDAQ:BDTXRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 61,027 shares on 8/19/2024Ownership: 0.597%Frazier Life Sciences Management L.P.Bought 16,216,216 shares on 8/16/2024Ownership: 9.354%Susquehanna Fundamental Investments LLCSold 30,044 shares on 8/15/2024Ownership: 0.043%AQR Capital Management LLCSold 66,440 shares on 8/15/2024Ownership: 0.032%The Manufacturers Life Insurance Company Bought 10,164 shares on 8/15/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions ERAS Stock Analysis - Frequently Asked Questions How have ERAS shares performed this year? Erasca's stock was trading at $2.13 at the start of the year. Since then, ERAS stock has increased by 34.3% and is now trading at $2.86. View the best growth stocks for 2024 here. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.12. When did Erasca IPO? Erasca (ERAS) raised $262 million in an IPO on Thursday, July 15th 2021. The company issued 17,500,000 shares at a price of $14.00-$16.00 per share. Who are Erasca's major shareholders? Erasca's top institutional shareholders include Frazier Life Sciences Management L.P. (9.35%), Logos Global Management LP (3.40%), Marshall Wace LLP (2.12%) and Affinity Asset Advisors LLC (1.44%). Insiders that own company stock include Jonathan E Lim, Bihua Chen, Alexander W Casdin and Valerie Denise Harding Start. View institutional ownership trends. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ERAS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.